Novartis: to present data at annual meeting

(CercleFinance.com) - Novartis will present data from more than 65 abstracts, including investigator-initiated trials, at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH) and the 2024 San Antonio Breast Cancer Symposium® (SABCS).


In particular, the group will be presenting the 96-week results of the Phase III Scemblix® ASC4FIRST trial in first-line Ph+ CML-CP, following the recent FDA approval based on 48-week data.

A presentation will also be given on the 4-year analysis of Kisqali®* on distant disease-free survival in key subgroups of patients with HR+/HER2- early breast cancer, from the NATALEE phase III study.

Product portfolio updates demonstrate the progress of research and development programs in hematological diseases and cancers.

' By prioritizing research in areas of greatest medical need and focusing on the early stages of disease, we aim to change the treatment paradigm for people who need additional therapeutic options, ' said Jeff Legos, Executive Vice President, Global Head of Oncology Development at Novartis.

' The new data presented at ASH and SABCS underscore our commitment to patients with cancer and blood disorders, and follow new expanded indications for Scemblix and Kisqali as well as recent updates to national treatment guidelines.

Copyright (c) 2024 CercleFinance.com. All rights reserved.